See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Nintendo
Natural Disasters
Tariffs
Social Media
Artificial Intelligence
Baseball
Donald Trump
Education
Eid
Autism
Senate
European Union
Published • loading... • Updated

MHRA approves trofolastat for prostate cancer diagnostic imaging

Summary by Medical Device Network
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for trofolastat (RoTecPSMA), a prostate-specific membrane antigen (PSMA)-targeting agent for detecting cancerous lesions in men with prostate cancer.The post MHRA approves trofolastat for prostate cancer diagnostic imaging appeared first on Medical Device Network.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Medical Device NetworkMedical Device Network

MHRA approves trofolastat for prostate cancer diagnostic imaging

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for trofolastat (RoTecPSMA), a prostate-specific membrane antigen (PSMA)-targeting agent for detecting cancerous lesions in men with prostate cancer.The post MHRA approves trofolastat for prostate cancer diagnostic imaging appeared first on Medical Device Network.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Medical Device Network broke the news in on Friday, March 28, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

London, England

London, England

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal